(RTTNews) - Shares of AnaptysBio Inc. (ANAB) are down over 50% from their 52-week high of $41.31, recorded last August, with the stock now hovering around the $20 level. This clinical-stage ...

“John brings decades of experience and an extens AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help ...

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...

He currently serves on the Boards of AnaptysBio (Nasdaq: ANAB), Design Therapeutics (Nasdaq: DSGN), Poseida Therapeutics (Nasdaq: PSTX), and Xeris Pharmaceuticals (Nasdaq: XERS), as well as the SPAC ...

Other companies are working in this areas, notably Eli Lilly which has a BTLA4 agonist called LY3361237 in phase 2 for systemic lupus erythematosus, and AnaptysBio which recently took ANB032 into ...

The company had been nominally out in front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with cobolimab, which is being tested alongside GSK’s PD-1 ...

“NOT GOOD” FOR BIOTECH SECTOR: RBC Capit AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the ...

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers ...

At close: 4:00:02 p.m. EDT ...

At close: April 17 at 4:00:02 p.m. EDT ...